Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Background: Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. Most people with this cancer can be cured. But those who are not cured have a poor prognosis. Researchers want to add another drug to standard treatment see if it can improve the cure rate. Objective: To see if the drug acalabrutinib given with rituximab and standard combination chemotherapy can improve the cure rate of aggressive B-cell lymphomas such as diffuse large B-cell lymphoma. Eligibility: People ages 18 and older with an aggressive B-cell lymphomas that have not been treated Design: Participants will be screened with: Blood and urine tests Physical exam Medical history Tumor biopsy Bone marrow biopsy: A needle will remove marrow from the participant s hipbone. Lumbar puncture: If necessary, a needle will remove fluid from the participant s spinal canal. Imaging scans Participants will take the study drug for up to 14 days. It is a pill taken 2 times a day. Then they will have more scans. They will get rituximab and chemotherapy. They may get these drugs through a needle in an arm vein. Or they may them through a tube placed in a vein in their chest or in their neck. They might also keep taking the study drug. Each treatment cycle lasts 21 days. They will have up to 6 cycles. Participants may have 4 doses of another drug injected into their spinal fluid. Participants will have repeats of the screening tests throughout the study. Participants will have a follow-up visit 30 days after their last treatment, then every 3 months for 2 years, then every 6 months for 3 years, and then yearly.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby w wieku 18 lat lub starsze z agresywnym chłoniakiem z komórek B, który nie był wcześniej leczony.
- •Choroba musi być potwierdzona w badaniach laboratoryjnych i obrazowych (np. węzły chłonne o wielkości co najmniej 1,5 cm).
- •Choroba musi być w stadium II, III lub IV.
- •Ogólny stan zdrowia dobry (tzw. sprawność wg ECOG 0-2), chyba że objawy wynikają z samej choroby.
- •Wystarczająca liczba niektórych komórek krwi (białych krwinek, czerwonych krwinek) i płytek krwi. Badanie pozwala na transfuzje, aby spełnić te wymagania.
- •Dostępność próbki guza do dalszych badań (archiwum lub świeża biopsja, jeśli potrzebne).
✗ Disqualifies
- •Pacjenci, którzy byli już leczeni z powodu chłoniaka z dużych komórek B.
- •Pacjenci, u których stwierdzono problemy z pracą serca, płuc, nerek lub wątroby, które nie wynikają bezpośrednio z chłoniaka i które są uważane za zbyt poważne.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- June 30, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
National Institutes of Health Clinical Center
Bethesda, United States
Trial contact
NCI Medical Oncology Referral Office
Christopher J Melani, M.D.
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.